The United States government has gone ahead and purchased 13 million doses of monkeypox vaccines from a Danish biotech company, who just happens to have very close ties with Dr. Anthony Fauci and the National Institute of Allergy and Infectious Diseases (NIAID) after there was a single case confirmed of monkeypox on American soil.
One case was confirmed by the Centers for Disease Control and Prevention (CDC), which was found in Massachusetts, and another was tested in New York City and was found to be positive for orthopoxvirus – a closely related virus to monkeypox.
In early May, six people are now being monitored after sitting next to an asymptomatic traveler on a flight from Nigeria to the United Kingdom.
Vaccines were purchased by the government after the first confirmed case, through the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services – who contacted the Danish biotech company Bavarian Nordic to stockpile the smallpox vaccines.
According to current data, the smallpox vaccine is around 85 percent effective in monkeypox and now the government has a $119 million stockpile of modified smallpox vaccines and the vaccines themselves will be freeze dried to extend shelf life and it is expected that manufacturing will kick off in 2023.
There is also an additional option to purchase a further $180 million worth of vaccines, which will amount to around 13 million freeze-dried doses.
Unsurprisingly, it is reported that Anthony Fauci has given Bavarian Nordic upwards of $100 million for research into smallpox vaccines in the early 2000s, around the same time that the federal government started to work with Bavarian Nordic.
Nearly 30 million doses have been provided to the U.S government by Bavarian Nordic, with most of it coming to the U.S before it was even given Emergency Use Authorization by the Food and Drug Administration in 2019.
The biotech company’s stock, BVNRY, has surged by more than 68 percent since it was announced that the U.S has purchased the bulk order. Countries across Europe are also starting to stockpile smallpox vaccines.
A financial news writer for InvestorPlace, Samuel O’Brient, said that the company’s current trajectory will see it boom.
“Bavarian Nordic is in the unique position of being able to provide a product that the entire world may soon need. Countries are still dealing with rising COVID-19 cases, and another infectious disease is the last thing anyone needs. A rare virus vaccine from a little-known drug maker may be about to prevent the next public health crisis,” O’Brient wrote.
“The COVID-19 vaccine rase ushered in a new biotech boom as investor focus shifted to the pharmaceutical sector. Wall Street may be about to see the same phenomenon play out as other biotech stocks rise on the momentum generated by a new vaccine champion.”